US officials urge to override Gilead patent

Most of US state attorney generals want the government to use its march-in-rights to license remdesivir to others

Remdisivir shows no benefits on COVID-19 patients in first clinical trial

Lancet paper contradicts Gilead results on drug which claimed improvement in patients  

Remdesivir: Predatory pricing of an unproven drug

Gilead Science’s price for the remdesivir drug reveals a faulty patents system and skewed policies of the United States

Gilead granted patent for hepatitis C drug Solvadi

The move is being seen as a possible impact of Indian Prime Minister Narendra Modi’s proposed visit to the US next month

India denies Gilead patent for hepatitis C drug, sofosbuvir

Companies that have not signed any licence agreement with US pharma giant are now free to produce generic versions of the drug

Gilead signs agreements with Indian generic companies for hepatitis C drug

Indian companies granted licence to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment …

Gilead expands hepatitis C licensing pacts with Indian companies

New programme introduces coercion and policing upon medical providers and may result in treatment interruptions for patients

COVID-19: US FDA grants emergency authorisation for remdesivir

EUA doesn't equal final nod; China trial painted different picture

US authority approves more efficacious hepatitis C drug

Sofosbuvir's prohibitive cost will put it out of reach of most patients in developing countries, including India

Medicines Pool Swirls

Drug companies are slowly joining the UN effort to offer life-saving patented medicines to poor countries but the terms are sometimes restrictive

The US takes on a drug giant

The US government's patent lawsuit against Gilead Sciences indicates it is tired of being milked by pharma companies

Rethinking IP think tank

Government sidelines its committee of experts to set up new panel to review India's intellectual property rights policy

Maths of Gilead's hepatitis C drug

Why US firm's super expensive drug sofosbuvir costs so much and how it can be made at a tenth of current price

COVID-19: Centre doesn’t clarify basis for CDSCO authorising remdesivir

Government also does not provide clarity about whether remdesivir should be given to only severe patients

Patent claim on hepatitis C drug questioned in many countries

With hepatitis C killing at least 700,000 people every year, civil society has strengthened efforts to make the drug accessible